Cannell & Co’s GenMark Diagnostics, Inc GNMK Stock Holding History

Cannell & Co’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,000	Closed	-$54K	–	262
2018 Q1	$54K	Hold	10,000	–	–	﹤0.01%	242
2017 Q4	$42K	Hold	10,000	–	–	﹤0.01%	248
2017 Q3	$96K	Hold	10,000	–	–	﹤0.01%	236
2017 Q2	$118K	Hold	10,000	–	–	﹤0.01%	238
2017 Q1	$128K	Hold	10,000	–	–	﹤0.01%	246
2016 Q4	$122K	Hold	10,000	–	–	﹤0.01%	242
2016 Q3	$118K	Hold	10,000	–	–	﹤0.01%	254
2016 Q2	$87K	Hold	10,000	–	–	﹤0.01%	253
2016 Q1	$53K	Hold	10,000	–	–	﹤0.01%	252
2015 Q4	$78K	Hold	10,000	–	–	﹤0.01%	260
2015 Q3	$79K	Hold	10,000	–	–	﹤0.01%	262
2015 Q2	$91K	Buy	+10,000	New	+$101K	﹤0.01%	264

Other funds holding GNMK

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co's GNMK Position: Q2 2018 in Review

Cannell & Co sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2018, closing a stake of 10,000 shares — an estimated $54K sold.

Cannell & Co first reported a position in GNMK in Q2 2015 and held it in 12 quarters. The position peaked at $128K in Q1 2017. 105 funds tracked by Wall St. Rank hold GNMK as of Q2 2018.

Cannell & Co reported no remaining GenMark Diagnostics, Inc position as of Q2 2018 after selling out during the quarter.
Cannell & Co sold 10,000 GenMark Diagnostics, Inc shares in Q2 2018, an estimated $54K.
Cannell & Co first reported a position in GenMark Diagnostics, Inc in Q2 2015 and held it in 12 quarters.
Cannell & Co's GenMark Diagnostics, Inc position peaked at $128K in Q1 2017.
105 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2018.

Based on Cannell & Co's 13F filing for Q2 2018, filed 6 Aug 2018.